188 related articles for article (PubMed ID: 28245187)
1. Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant.
Rodríguez-Jiménez C; García-Saiz M; Pérez-Tamajón L; Salido E; Torres A
Drug Metab Pers Ther; 2017 Mar; 32(1):49-58. PubMed ID: 28245187
[TBL] [Abstract][Full Text] [Related]
2. Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.
Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
Transplantation; 2012 Nov; 94(9):971-7. PubMed ID: 23073467
[TBL] [Abstract][Full Text] [Related]
3. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
[TBL] [Abstract][Full Text] [Related]
4. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
Miao LY; Huang CR; Hou JQ; Qian MY
Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
6. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
Lee J; Huang H; Chen Y; Lu X
Biopharm Drug Dispos; 2014 Apr; 35(3):164-72. PubMed ID: 24285256
[TBL] [Abstract][Full Text] [Related]
7. Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.
Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
Transplantation; 2011 Dec; 92(12):1342-7. PubMed ID: 22094953
[TBL] [Abstract][Full Text] [Related]
8. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
[TBL] [Abstract][Full Text] [Related]
9. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.
Li Y; Yan L; Shi Y; Bai Y; Tang J; Wang L
Springerplus; 2015; 4():637. PubMed ID: 26543771
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients.
Woillard JB; Kamar N; Coste S; Rostaing L; Marquet P; Picard N
Clin Chem; 2013 Dec; 59(12):1761-9. PubMed ID: 23974086
[TBL] [Abstract][Full Text] [Related]
13. CYP3A5 and ABCB1 polymorphisms in living donors do not impact clinical outcome after kidney transplantation.
Yang L; de Winter BC; van Schaik RH; Xie RX; Li Y; Andrews LM; Shuker N; Bahmany S; Koch B; van Gelder T; Hesselink DA
Pharmacogenomics; 2018 Jul; 19(11):895-903. PubMed ID: 29991328
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.
Sun B; Guo Y; Gao J; Shi W; Fan G; Li X; Qiu J; Qin Y; Liu G
Pharmacogenomics; 2017 Nov; 18(16):1503-1513. PubMed ID: 28952408
[TBL] [Abstract][Full Text] [Related]
15. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
17. The CYP3A5 and ABCB1 Gene Polymorphisms in Kidney Transplant Patients and Establishment of Initial Daily Tacrolimus Dosing Formula.
He Y; Ma Y; Fu Q; Liang J; Yu X; Huang H; Zhong L; Huang B
Ann Pharmacother; 2022 Apr; 56(4):393-400. PubMed ID: 34362271
[TBL] [Abstract][Full Text] [Related]
18. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
[TBL] [Abstract][Full Text] [Related]
19. The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients.
Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Biondi F; Sanguedolce R; Vizzini G; Palazzo U; Polidori P; Triolo F; Gridelli B; D'Alessandro N
Ann Transplant; 2009; 14(1):23-31. PubMed ID: 19289993
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
